SPLITOAK STRATEGIES LLC for ALKERMES, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 22, 2024 | $50,000 | Replaced |
| 2nd Quarter - Amendment | Oct 21, 2024 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Proposed Rule (CMS-2434-P) -- and operational and patient access challenges with stacking policy
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Health Issues HCR
Awareness of the need for access to all FDA-approved medications for treatment of substance use disorder; Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments for substance use disorder and alcohol use disorder; Initiatives to promote the use of relapse prevention post detoxification; H.R.4531/S.3393 Support for Patients and Communities Reauthorization Act; Advance the use and funding of FDA-approved medicines to treat serious mental illness in criminal justice and public health settings
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.